Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

T Cell Persistence Test Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

T Cell Persistence in TCR-T Therapy

In the context of TCR-T therapy, T cell persistence refers to the ability of TCR-T cells to persist in the body after infusion. The persistence of TCR-T cells is important for their efficacy, as they need to remain in the body in sufficient numbers to continue targeting and killing cancer cells, leading to long-term antitumor activity. Good persistence of TCR-T cells can improve the effective antitumor response. Several factors can influence TCR-T cell persistence, including TCR-T cell designs and manufacturing processes, the type of TCR-T cell, the type and stage of the cancer being treated, and the patient's immune system.

At Creative Biolabs, we provide T-cell persistence test services that can be used to detect TCR-T cell persistence in vivo. Our experts offer several methods to monitor circulating TCR T-cells into blood samples after treatment.

Our Services

It is essential to understand and enhance TCR-T cell persistence thus improving the efficacy and durability of TCR-T cell therapies in treating cancer. T cell persistence test involves the detection and quantification of TCR T cells in blood samples. At Creative Biolabs, we monitor TCR T-cell persistence over time with several techniques, including flow cytometry, qPCR, and ddPCR. By combining multiple techniques, we aim to provide comprehensive information on TCR-T cell persistence and function, which is crucial for the optimization of TCR-T cell therapies. The following are some reliable methods of tracking TCR T cell numbers.

Fig.1 T Cell Persistence Tests.

• Flow cytometry

Flow cytometry enables the identification of surface epitopes on live TCR T-cells. This method involves staining the TCR-T cells with fluorescent antibodies specific to the TCR molecule and other cell surface markers. The stained cells are then analyzed using flow cytometry to quantify the number of TCR-T cells present in a sample.

• qPCR

qPCR is the gold standard for the detection and quantification of the integrated TCR transgene sequence in TCR-T cells. Monitoring TCR-T expansion/persistence through our qPCR assay gives you real-time data on the TCR-T therapy.

• ddPCR

ddPCR is a powerful tool that can be used to determine the absolute number of TCR-T cells present in a blood sample. It enables the monitoring of TCR T-cell kinetics with high precision and sensitivity.

Support Data

Here are some representative data for T-cell persistence tests.

Case 1: Analysis of TCR-T Cell Persistence by Flow Cytometry.

Fig.2 TCR-T cell persistence with time was assessed by flow cytometry.¹

Case 2: Analysis of TCR-T Cell Persistence by qPCR.

Fig.3 TCR-T cell persistence with time was assessed by qPCR.²

Case 3: Analysis of CAR-T Cell Persistence by ddPCR

Fig.4 CAR-T cell persistence with time was assessed by ddPCR.³

References

1. Drakes, Dylan J., et al. "Lymph node-targeted vaccine boosting of TCR-T cell therapy enhances anti-tumor 1 function and eradicates solid tumors." bioRxiv (2022): 2022-05.
2. Pan, Qiuzhong, et al. "Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗ 02: 01 patients with advanced soft tissue sarcoma." Cell Reports Medicine 4.8 (2023).
3. Wittibschlager, Valerie, et al. "CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma." International journal of molecular sciences 24.6 (2023): 5688.